



The Current Development of Glycoconjugate Vaccines for Infectious Diseases

Guest Editor:

Dr. Fatme Mawas

Vaccines Division, Science,
Research & Innovation Group,
MHRA, Potters Bar, UK

Deadline for manuscript
submissions:

closed (31 December 2025)

Message from the Guest Editor

Glycoconjugate vaccines were successful against *H. influenzae* b (Hib) in the 1980s, leading to the development of other conjugate vaccines. However, chemical conjugation has limitations such as variability, high costs, and low recovery.

Biological conjugation, such as glycoengineering of recombinant vaccines in bacteria, bypasses these issues. Another alternative method is using Multiple Antigen Presenting Systems (MAPS) to produce glycoconjugate vaccines. This special issue highlights recent scientific knowledge and progress in the field of conjugate vaccines.

In this special issue on conjugate vaccines, we invite you to contribute an original report, observation, or review. Your contribution should focus on the development and evaluation of conjugate vaccines against infectious diseases, novel carrier proteins, recent advances in production technologies, and improvements in characterization methods. Specifically,

1. development and evaluation of conjugate vaccines against infectious diseases,
2. novel carrier proteins,
3. recent advances in novel technologies for conjugate vaccine production,
4. improvements in methods for conjugate vaccine characterization.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition
and Behavior, University College
Roosevelt, 4331 CB Middelburg,
The Netherlands

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

Journal Rank: JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com
[X@Vaccines_MDPI](https://twitter.com/Vaccines_MDPI)